Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug…
Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027…
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…
